This report employed the SQUIRE publication guidelines for reporting healthcare quality improvement research. [Ogrinc G, Davies L, Goodman D, et al. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.
| WHAT IS KNOWN AND OBJECTIVE
Medication errors are a significant cause of morbidity and mortality and may occur at any stage during prescription, preparation, dispensing or administration of drugs. Errors with antineoplastic drugs are particularly hazardous owing to their mechanism of action and narrow therapeutic index (TI) and the frequently poor performance status of cancer patients. In a retrospective analysis of mortality associated with medication errors, antineoplastic drugs were the second most common cause of involvement in death. The introduction of the gravimetric approach to preparation of IV agents supported by expert software aims to reduce the potential for errors associated with visual inspection. At each stage of drug preparation, measured solutions are weighed on an electronic balance and results related to the density of the components were stored in the system's database. In this way, the accuracy of the prepared volume is checked to ensure it falls within acceptable margins for error. Figure 1 provides a visual comparison of the volumetric (with syringes being a main driver of inaccuracy [ Figure 2 ] 5 ) and gravimetric methods of preparation of prescribed doses.
European guidance supports the use of the computer-assisted gravimetric approach for preparation of individualized ready-to-use cytostatic solutions, 4 and systems have been introduced in many pharmacies in Europe. However, little research has been reported on the evaluation of the extent and prevalence of medication errors and their potential for prevention by gravimetric systems. Results of a recent US single-centre study using gravimetric IV workflow software system showed an error detection rate of 7% in 15 843 doses prepared in an oncology ambulatory care pharmacy, with 71% detected during gravimetric weighing. The oncology setting was chosen due to the narrow margin of safety for many chemotherapy solutions and the high volume of IV medicines specifically compounded for individual patients in dedicated units. 
| METHODS

| RESULTS
Error tolerance levels set by centres varied from 2.5% to 6%, and the maximum difference in preparation tolerance was 3.5%. However, extended tolerances of up to 30% (range 3.1% to 30%) were found for medications that are formulated in a manner difficult to stay within normal limits for preparation (Table 1) . Medicines most frequently assigned extended tolerances included bortezomib, vincristine, methotrexate and cytarabine. Tolerance ranges for these and other medicines were highly variable; for example, the extended tolerance for bortezomib at centre 6 was 3.1-3.98, compared to 12.11-20.63 at centre 9.
The proportion of antineoplastic drug samples that were outside centre tolerance levels ranged from 5.65% to 16.37% with an overall proportion of 7.89% ( Table 1 ). The mean error rate across centres
antineoplastic agents, gravimetric IV workflow software system, medication errors, preparation, safety (adjusting for unequal number of preparations at different centres) was 10.44%. It might have been expected that centres with the lowest tolerance for error would have the highest error rates but, in our study, the centre with the lowest number of preparations out of tolerance (OOT) (centre 3) had one of the lowest tolerance levels. In contrast, the centre with the highest percentage of OOT preparations (centre 7) had a relatively high tolerance threshold (5%).
Excluding preparations with extended tolerances >10%, the proportion of antineoplastic preparations with deviations >10% of target dose ranged from 0.49% to 5.04% across sites, with a mean of 2.25%. The proportion of preparations with deviations >20% of target dose ranged from 0.21% to 1.27% across sites, with a mean of 0.71%
( Table 2 ).
The centre with the highest proportion of OOT preparations (centre 7: 16.37%) also showed the poorest performance with deviations >10% (5.04%) and >20% (1.1%) ( Tables 1 and 2 ).
Analysis of antineoplastic preparations compounded correctly at first attempt showed that 9.5% of doses were not effectively prepared "at the first attempt" (range 6.6% to 19%) ( Table 1 ). The average proportion of preparations requiring more than one attempt across hospitals (adjusting for unequal number of preparations at different centres) was 13.77%. The need for repeat preparation was most common at centres with the highest proportion of OOT preparations.
Further analyses show that antineoplastic preparations were more likely to be OOT when very small amounts of drug were being prepared ( Figure 3 ) and that, at most centres, levels of
Tolerance of 1-and 5-mL syringes (<5 mL nominal capacity [NC]: allowed tolerance of ±5% on expelled volumes [EVs] that are equal to or greater than half the NC. For EVs that are less than half the NC, the tolerance obtained is ±1.5% of the NC +2% of the EV. ≥5 mL NC: tolerance is reduced to ±4% on EVs that are equal to or greater than half the NC, and for EVs that are less than half the NC, the tolerance is obtained as ±1.5% of the NC +1% of the EV) 
| DISCUSSION
This analysis showed that 7.89% of 759 060 doses of antineoplastic drugs prepared across the 10 study centres had error levels outside the accepted tolerance range set by each centre; it is highly likely these errors would have gone undetected using traditional volumetric preparation. When this figure was adjusted to equally weigh the centres and their extent of service provision for preparation of antineoplastic agents, the mean OOT rate was 10.44%.
T A B L E 1 Error tolerance level (%), number of preparations out of tolerance (%), number of preparations not prepared correctly at first attempt (%) and range of extended tolerance (%) for centres in the study F I G U R E 3 Predicted probability of preparation out of tolerance vs. prescribed dosage amount F I G U R E 4 Predicted probability of preparation out of tolerance vs. total number of preparations per centre
The overall error level seen with antineoplastic drugs was consistent with that seen for all preparations in the study (antineoplastic and non-antineoplastic, n=1 199 400, OOT 9%), and trends for different centres were also similar.
To our knowledge, this is the first large-scale retrospective research that analysed data from real-time log files which record all events during the preparation process for IV antineoplastic drugs. This made it possible to apply statistical methods to describe relationships and deviations which occurred and identify medication errors which would otherwise have gone unrecognized.
The OOT error level in our study is in accordance with the 7% error rate identified in 15 843 IV drug doses prepared in a single oncology ambulatory care pharmacy in the USA; 6 71% of these were detected gravimetrically. At the same pharmacy, 51 037 chemotherapy doses prepared without using the gravimetric workflow software system had a self-reported error rate of just 0.096% (74-fold less than with automated gravimetric software system).
All errors in our multicentre study and in the single-centre US study were detected during the preparation process and did not need to be corrected post-production. In the US study, this resulted in reductions of 34% of technician production time and 37% of pharmacist checking time.
Although the overall OOT error rate in our study was 7.89%, five centres had levels >10%, the highest being >16%. Centres with the highest overall error rates also tended to have higher rates of "not at first attempt" errors and of errors >10% and >20% OOT.
Logistic regression identified significant relationships between OOT error rates and other recorded variables, including between
OOT error rates and each drug's total number of preparations (P<.005). With few exceptions among centres, the more often an individual drug was prescribed, the less likely that an OOT dosing error was made ( Figure 4) . The probability of a preparation being outside tolerance generally fell rapidly as the number of drug preparations increased over 500 preparations (measured during the first 10 000 preparations). A continuing decline in error rate was recorded at centres with highest preparation levels for individual drugs, reaching very low levels at centres preparing individual drugs ≥1500 times. The reduction in dosing errors was significant (P<.05) for all centres except two (centre 1 P=.13 and centre 7 P=.62) and is likely to have reflected increased experience with preparation methodology.
How important are medication errors that are >10% and >20% of target dose? Regulatory authorities such as the European Medicines Agency (EMA) require that, to show bioequivalence, 90% confidence interval of the ratio of the area under the curve (AUC) for two drugs must fall within the range of 80% to 125%. 2, 7 For drugs with a narrow TI, the EMA recommends the range be 90% to 111.11%. It is therefore reasonable to suggest that medication deviations from 80% to 125% for most drugs and 90% to 111.11% for those with a narrow TI-as is the case for many antineoplastic agents-can be considered problematic.
Accepted stability levels for drug preparations also provide useful insights about appropriate tolerance levels for medication errors.
Pharmaceutical scientists commonly regard a stability limit of 90% as acceptable. 8 However, recent European guidance on practical stability studies of anticancer drugs draws attention to the need to consider TI, variability in pharmacokinetic/pharmacodynamics (PK/PD) and T A B L E 3 Out-of-tolerance rates (N and %) and total preparations (N) for drugs with highest out-of-tolerance rates (only drugs with out-of tolerance rates >10% are shown) specific clinical use, and risks related to degradation of products. The guidance suggested that the classical limit of 10% of degradation may be inappropriate in some cases.
9
The narrow TI of anticancer drugs requires exact dosing to obtain sufficient pharmacological activity and minimize toxicity. Further, clinical effectiveness of antineoplastic regimens is complicated by interpatient variability, genetic polymorphisms in drug-metabolizing enzymes and drug-drug interactions caused by polymedication.
10
Whereas clinical factors are difficult to control, the variability of pharmacological factors may be lessened by introducing sophisticated methods that reduce the error margin in the preparation of antineoplastic agents. In our study, we found that the volumetric preparation method is unable to sufficiently detect the compounding variability that causes preparation errors. A preparation error threshold of 10% was chosen for our evaluation, based on previously published studies 11, 12 and the Société Française de Pharmacie Oncologique (SFPO)/European Society of Oncology Pharmacy (ESOP) guidelines 9 used in European countries. The German Pharmacopoeia DAB 10 already states in its monograph "V.5.2 Uniformity of single dose drugs" that for parenteral drugs, dosing deviation must stay within ±10% and ±15% for doses >40 and <40 mg, respectively.
13
This monograph has been replaced by the European Pharmacopoeia general chapters on uniformity of mass of single-dose preparations (2.9.5), uniformity of content of single-dose preparations (2.9.6) and uniformity of dosage units (2.9.40) with a more sophisticated statistical approach.
14 Other sources 15, 16 allow a variation of only 5%, based on volumetric preparation processes. However, the results of this study demonstrate that the final doses checked by gravimetric measurement are often in a range that can be very much higher than the assumed 5%.
With these factors in mind, oncology pharmacists may also need to take such parameters into account when deciding appropriate error tolerance levels for different antineoplastic agents.
Our study demonstrated a mean rate of deviations >10% of 2.25% (range 0.49% to 5.04% across sites) and a mean average rate of deviations >20% of 0.71% (range 0.21% to 1.27% across sites), after excluding preparations with extended tolerances >10% and >20%, respectively. This suggests data retrieved from the gravimetric workflow system verified nearly 13 831 doses of antineoplastic agents that could have been administered to patients at levels which may have had a negative impact on therapeutic outcome.
Possible therapeutic impact gains associated with the use of the gravimetric approach need to be considered within the context of the tolerance settings applied by system administrators. Standard preparation tolerances set by centres fell within a relatively narrow range (2.5% to 6%) with extended preparation tolerances showing much wider variation (3.1% to 30%).
The extended range applies to drugs whose formulation makes it very difficult to stay within normal limits for preparation, and generally applies to drugs requiring low volumes/masses (eg <2000 mg). The lower the solution mass, the higher the tolerance. The high extended tolerances used at some centres indicate that it may be difficult to achieve adequate dosing accuracy for some drugs. However, the variation in extended tolerances for some drugs, reported across centres, merits further investigation.
The challenge of minimizing dosing errors when working with very small amounts of drug is clearly demonstrated in our study ( Figure 3 ). The probability of preparations being OOT fell rapidly as prescribed dosages increased up to 1000 mg and were almost zero at most centres when doses of ≥3000 mg were prepared. One explanation could be that drugs prepared at higher volumes contain more active ingredient and require larger amounts of diluent during preparation. These high-volume formulations are therefore less likely to result in withdrawal of an incorrect dose compared with low-volume drugs, such as bortezomib (see extended tolerances above).
Tolerance levels set by centres in our study were particularly exceeded for certain drugs. For example, nearly 60% of teniposide preparations and over half of those of alemtuzumab were OOT (Table 3) . Neither drug was commonly prescribed, so it might be considered that the high error rates were in line with another finding from the study that the less often an individual drug was prescribed, the more likely an OOT dosing error was to occur. However, as error rates were also high for some other more commonly prescribed medicines, such as bortezomib, unfamiliarity with preparation cannot be the only reason for OOT variations for different drugs. As different centres used different technical equipment for preparing drugs, this may have influenced variability for different medicines, but the contribution to possible negative outcomes needs to be further investigated.
Our findings are relevant both to centres that have already implemented a gravimetric measurement system and to those still using traditional volumetric systems for preparing antineoplastic drugs, which may not achieve effective recognition of medication errors.
Possible limitations of our research include a lack of information about devices used during the preparation process and how these may impact on occurrence of medication errors. Variation between participating centres in use of needles, chemospikes and safety devices aimed at reducing contamination due to aerosol generation may affect risk of medication errors.
As this was a retrospective study, we were unable to ensure standardization of preset error tolerance levels. The 3.5% difference in preparation tolerance between centres may have affected the variation in number of first withdrawals that are out of tolerance, but was not far from the aimed 2% difference.
Standardized density values for different antineoplastic drugs used in the study were stored in the database of the gravimetric software. set by any centre did not exceed 6%, this remains well below the 10% threshold for bioequivalence that the EMA considers relevant for drugs with a narrow TI.
Use of different antineoplastic agents varied across the centres in the study. Hence, the contribution of some centres to error rates with certain drugs may have been disproportional.
| WHAT IS NEW AND CONCLUSION
The evaluation of data from 10 centres in five European countries has shown that the introduction of a gravimetric preparation system for antineoplastic agents can detect and prevent medication errors which would not have been recognized by traditional methods.
These may have caused serious toxicity or underdosing, potentially resulting in suboptimal outcomes for patients undergoing anticancer treatment.
Using logged data during gravimetric preparation of drugs, it was possible to identify the previously unreported dimension and potential impact of volume errors during medication preparation. At the same time, it was possible to show that a gravimetric IV workflow software system is capable of largely eliminating this kind of potentially lifethreatening medication error.
The demonstration that some antineoplastic drugs are more prone to volume errors than others, and that errors are particularly common when prescribed dosages are lowest, should inform research into future improvements in formulations.
European guidance already supports the use of the computerassisted gravimetric approach for preparation of individualized ready-to-use cytostatic solutions, 4 and obligatory implementation of gravimetric methodology for medication preparation is overdue.
